BLL Stock Recent News

Vancouver, Canada, May 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates.

WESTMINSTER, Colo. , May 12, 2025 /PRNewswire/ -- Ball Corporation ("Ball") (NYSE: BALL) announced today that it priced an underwritten public offering of €850 million aggregate principal amount of 4.250% Senior Notes due 2032 (the "Notes").

[12/05/2025] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [Ball Corporation] Pre-stabilisation Period Announcement BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222 hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation EU/2016/1052 under the Market Abuse Regulation (EU/596/2014).

WESTMINSTER, Colo. , May 12, 2025 /PRNewswire/ -- Ball Corporation ("Ball") (NYSE: BALL) announced today that it has commenced an underwritten public offering of €750 million aggregate principal amount of Senior Notes due 2032 (the "Notes").

BALL's Q1 results reflect gains from higher volumes and price/mix across all segments.

Ball Corporation (NYSE:BALL ) Q1 2025 Earnings Conference Call May 6, 2025 11:00 AM ET Company Participants Brandon Potthoff - Director of Investor Relations Dan Fisher - Chief Executive Officer Howard Yu - Chief Financial Officer & Executive Vice President Conference Call Participants Ghansham Panjabi – Baird Stefan Diaz - Morgan Stanley Anthony Pettinari - Citi Phil Ng - Jefferies Edlain Rodriguez – Mizuho Josh Spector - UBS George Staphos - Bank of America Jeffrey Zekauskas - J.P. Morgan Michael Roxland - Truist Chris Parkinson - Wolfe Research Arun Viswanathan - RBC Operator Greetings, and welcome to the Ball Corporation First Quarter 2025 Earnings Conference Call.

Although the revenue and EPS for Ball (BALL) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ball (BALL) came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.68 per share a year ago.

Highlights First quarter U.S. GAAP total diluted earnings per share of 63 cents vs. $11.61 in 2024 First quarter comparable diluted earnings per share of 76 cents vs.

BALL's Q1 results are likely to reflect the impacts of the recent decline in customer demand, partially offset by positive pricing.